THERAPEUTIC CLASS

Serum Levels of FGF21 and Prediction of Cardiovascular Events

---

Over the last decade, the discovery of endocrine fibroblast growth factors (eFGFs) and their signaling pathways with regulatory functions in cell metabolism, but not proliferation, is among the major breakthroughs in the field of endocrinology and metabolism [1, 2]. Among eFGFs, FGF21 has attracted much attention as a potential pharmacotherapy against major metabolic diseases, such as obesity, diabetes, fatty liver disease, cardiometabolic diseases, and collateral tissue damage, as demonstrated in both animal models and human clinical patients [3–5].

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Nevodio
Cardiovascular & Hematopoietic System

Specific Detail Info

Cardiology 2018;139:219–221

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment